Patent Issued for Neoantigens expressed in ovarian cancer and their uses (USPTO 11945881).
In: Cancer Gene Therapy Week, 2024-04-22, S. 119-119
serialPeriodical
Zugriff:
A patent has been issued to Janssen Biotech Inc. for neoantigens expressed in ovarian cancer and their potential uses in therapies against the disease. Ovarian cancer is a leading cause of cancer-related deaths in women, with a high risk of recurrence and poor survival rates. The patent discloses isolated polypeptides and polynucleotides that could be used in the development of new treatments for ovarian cancer, including cases that are relapsed, refractory, or platinum-resistant. The patent describes various vectors, including adenovirus, poxvirus, adeno-associated virus, retrovirus, and self-replicating RNA molecules, that can be used in the treatment of ovarian cancer. These vectors contain polynucleotides that encode multiple polypeptides, which can be connected to each other in any order. The patent also mentions a pharmaceutical composition comprising the vector. For more detailed information, please refer to the full patent. [Extracted from the article]
Copyright of Cancer Gene Therapy Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Neoantigens expressed in ovarian cancer and their uses (USPTO 11945881).
|
---|---|
Zeitschrift: | Cancer Gene Therapy Week, 2024-04-22, S. 119-119 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6837 (print) |
Schlagwort: |
|
Sonstiges: |
|